Actinium Pharmaceuticals, Inc.

ATNM NYSE SEC CIK 1388320
Follow Actinium Pharmaceuticals Weekly email: filings, results, news

Financials

Reported figures only · latest: Q2 2026 USD · US GAAP
Revenue, last quarter $35M
Net income $27.9M +505.7% vs same quarter last year
EPS, diluted $0.89 +504.5% vs same quarter last year
Operating cash flow −$5.2M +4% vs same quarter last year
Revenue by quarter
$90K
$0
$35M
Q3 25 Q4 25 Q2 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$60M−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$90K−$33.9M
FY24-−$38.2M
FY23$81K−$48.8M
FY22$1M−$33M
FY21$1.1M−$24.8M
FY20-−$22.2M
FY19-−$21.9M
FY18-−$23.7M
FY17-−$26.6M
FY16-−$24.3M
FY15-−$21M
FY14-−$24.7M
FY13-−$10.8M
FY12-−$8.4M
FY11$0−$3.4M
MarginsShare of revenue
  • Operating margin
  • Net margin
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearOperating marginNet margin
FY25−40274.4%−37652.2%
FY24--
FY23−64098.8%−60269.1%
FY22−3311.1%−3205.5%
FY21−2182.2%−2165.6%
FY20--
FY19--
FY18--
FY17--
FY16--
FY15--
FY14--
FY13--
FY12--
FY11--
Free cash flowOperating cash flow minus capital expenditure
−$60M−$40M−$20M$0$20MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$24.7M
FY24−$33.1M
FY23−$47.5M
FY22$8.3M
FY21−$21M
FY20−$21.9M
FY19−$21.5M
FY18−$20.7M
FY17−$21.6M
FY16−$20.8M
FY15−$18.6M
FY14−$14.5M
FY13−$6.3M
FY12−$5.2M
FY11-
Net margin vs the sectorMedian of Healthcare companies filing with the SEC
  • Actinium Pharmaceuticals
  • Healthcare median
−80000%−60000%−40000%−20000%0%FY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearActinium PharmaceuticalsHealthcare median
FY25−37652.2%−40.6%
FY24-−60.7%
FY23−60269.1%−97.1%
FY22−3205.5%−128.5%
FY21−2165.6%−129.2%
FY20-−136.5%
FY19-−133.7%
FY18-−173.4%
FY17-−176.7%
FY16-−164.8%
FY15-−183.4%
FY14-−133%
FY13-−88.5%
FY12-−87.4%
FY11-−76.3%

News

No stories filed under Actinium Pharmaceuticals yet - coverage appears here as the news feed clusters it.